Silo Pharma Receives Japan Notice of Allowance for SPC-15 PTSD Intranasal Therapy Patent Application
Reuters
Feb 18
<a href="https://laohu8.com/S/SILO">Silo Pharma</a> Receives Japan Notice of Allowance for SPC-15 PTSD Intranasal Therapy Patent Application
Silo Pharma Inc. said the Japan Patent Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an intranasal therapeutic targeting PTSD. The application includes composition and method claims for preventing or mitigating stress-induced behavioral responses and is expected to be granted shortly.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602180828PRIMZONEFULLFEED9656283) on February 18, 2026, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.